Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
27.28
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
99
100
Next >
Which S&P500 stocks are the most active on Friday?
↗
October 31, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the most active S&P500 stocks in today's session.
Via
Chartmill
The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future
October 31, 2025
The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by...
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
October 31, 2025
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of...
Via
TokenRing AI
Topics
Artificial Intelligence
Supply Chain
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
↗
October 30, 2025
Via
Stocktwits
AI Revolutionizes Pharma Supply Chains: A New Era of Localized Resilience and Efficiency
October 31, 2025
The pharmaceutical industry is experiencing a profound and immediate transformation as Artificial Intelligence (AI) becomes a strategic imperative for localizing supply chains, fundamentally enhancing...
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
Fraud
AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
October 31, 2025
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to...
Via
TokenRing AI
Topics
Artificial Intelligence
Intellectual Property
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer
↗
October 30, 2025
Via
Stocktwits
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
October 31, 2025
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...
Via
TokenRing AI
Topics
Animal Testing
Artificial Intelligence
Economy
Why iRhythm (IRTC) Stock Is Trading Up Today
October 31, 2025
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 3.2% in the afternoon session after it reported strong third-quarter financial results that surpassed expectations and...
Via
StockStory
Topics
Artificial Intelligence
World Trade
AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%
↗
October 31, 2025
AbbVie stock dipped early Friday, though the drug giant easily beat views.
Via
Investor's Business Daily
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
↗
October 31, 2025
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Via
Stocktwits
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down
October 31, 2025
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via
StockStory
Edwards Lifesciences Pops As Third-Quarter Beat Lifts 2025 Guidance
↗
October 30, 2025
Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly calls.
Via
Investor's Business Daily
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
↗
October 30, 2025
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
Via
Benzinga
Topics
ETFs
Thursday's session: most active stock in the S&P500 index
↗
October 30, 2025
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market...
Via
Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
↗
October 30, 2025
Let's dive into the action on the US markets on Thursday. Here are the most active stocks that are driving the market today.
Via
Chartmill
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
↗
October 30, 2025
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Via
Investor's Business Daily
Topics
Economy
Government
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
↗
October 30, 2025
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.
Via
Benzinga
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
↗
October 30, 2025
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.
Via
Investor's Business Daily
Pfizer Addresses Proposal for Metsera
October 30, 2025
From
Pfizer Inc.
Via
Business Wire
Prediction: Putting $1,000 Into These Dividend Stocks Could Pay Off for Years
↗
October 30, 2025
Investing in high-quality stocks with generous dividend payouts can help you gradually build substantial wealth.
Via
The Motley Fool
2 High-Yield Stocks With Fresh Catalysts
↗
October 29, 2025
Income investors can capture yields above 5% from companies executing business transformations.
Via
The Motley Fool
Topics
Lawsuit
S&P 500 Healthcare Sector Navigates Mixed Market Waters on October 29, 2025
October 29, 2025
On October 29, 2025, the broader market exhibited a decidedly mixed performance, reflecting a prevailing sense of uncertainty among investors. Against this backdrop of fluctuating sentiment, the S&P...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
'I Still Can't Believe It's Around': Cramer Rips Plug Power
↗
October 29, 2025
Mad Money Lightning Round: Jim Cramer says Sempra (SRE) is a buy, supported by Wells Fargo's Overweight rating. Pfizer (PFE) and Dow (DOW) discussed. Plug Power (PLUG) faces concerns over shareholder...
Via
Benzinga
Topics
Stocks
1 S&P 500 Stock to Target This Week and 2 We Brush Off
October 29, 2025
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...
Via
StockStory
Topics
Stocks
Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety
↗
October 28, 2025
Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for pregnant women.
Via
Benzinga
Topics
Lawsuit
Why NeoGenomics (NEO) Stock Is Trading Up Today
October 28, 2025
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations.
Via
StockStory
Topics
World Trade
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
October 27, 2025
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
3 Dividend-Paying Drug Stocks to Buy at a Discount
↗
October 27, 2025
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?
Via
The Motley Fool
Topics
Intellectual Property
What Is 1 of the Best Pharmaceutical Stocks to Buy Now?
↗
October 27, 2025
This pharma giant is entering the rapidly expanding market for weight loss drugs.
Via
The Motley Fool
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.